Literature DB >> 4019781

Role of the kidneys in the metabolism of plasma mevalonate. Studies in humans and in rhesus monkeys.

D J McNamara, E H Ahrens, T S Parker, K Morrissey.   

Abstract

Studies were carried out in humans and in rhesus monkeys to determine the role of the kidneys in the metabolism of circulating mevalonic acid (MVA). Following intravenous infusion of [14C]MVA and [3H]cholesterol, there was a rapid appearance of [14C]squalene in the kidneys that exhibited a significantly longer half-life than plasma or hepatic squalene. In man and in rhesus monkeys there was a rapid equilibration between newly synthesized cholesterol from MVA and exogenously administered cholesterol in all tissues except the kidneys, where the specific activity ratio of newly synthesized to exogenous cholesterol was significantly higher. Estimates of the quantitative metabolism of intravenously infused radiolabeled MVA in the monkey demonstrated that 23% was excreted in the urine, 67% metabolized to cholesterol (58% in nonrenal tissues and 9% in the kidneys), and 10% catabolized to CO2 and nonsteroid products. Measurements of MVA metabolism in anephric and uninephric patients demonstrate that, in the absence of renal uptake of MVA, exogenous and newly synthesized cholesterol achieve almost instantaneous equilibrium in the plasma; whereas in control subjects with normal renal function, this equilibration required at least 21 d for the two cholesterol decay curves to become parallel. These results suggest that the kidneys are solely responsible for the observed disequilibrium between newly synthesized and exogenous cholesterol; we suggest that this was due to the delayed release of newly synthesized cholesterol from the kidneys into the plasma compartment following intravenous infusion with radiolabeled MVA. The data document the importance of the kidneys in the metabolism of circulating MVA. However, calculation of the quantitative significance of this pathway in relation to whole body MVA metabolism indicates that renal metabolism of MVA accounts for approximately 0.1% of daily MVA turnover, and that alterations in this pathway due to any form of renal pathology would not result in significant changes in hepatic or whole body sterol synthesis rates. We urge caution in the use of radiolabeled MVA in long-term kinetic studies of sterol metabolism because our data show that the plasma compartment of MVA is not necessarily in isotopic equilibrium with tissue MVA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4019781      PMCID: PMC423696          DOI: 10.1172/JCI111962

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Measurement of squalene in human tissues and plasma: validation and application.

Authors:  G C Liu; E H Ahrens; P H Schreibman; J R Crouse
Journal:  J Lipid Res       Date:  1976-01       Impact factor: 5.922

2.  Transfer of carbon atoms from mevalonate to n-fatty acids.

Authors:  J Edmond; G Popják
Journal:  J Biol Chem       Date:  1974-01-10       Impact factor: 5.157

3.  Lipid biosynthesis from DL (2- 14 C) mevalonic acid in intact mice and rabbits.

Authors:  B Edgren; K Hellström
Journal:  Acta Physiol Scand       Date:  1972-10

4.  The in vitro metabolism of mevalonate by sterol and non-sterol pathways.

Authors:  M Righetti; M H Wiley; P A Murrill; M D Siperstein
Journal:  J Biol Chem       Date:  1976-05-10       Impact factor: 5.157

5.  Metabolism of mevalonate in rats and man not leading to sterols.

Authors:  A M Fogelman; J Edmond; G Popjåk
Journal:  J Biol Chem       Date:  1975-03-10       Impact factor: 5.157

6.  The quantitative role of the kidneys in the in vivo metabolism of mevalonate.

Authors:  M H Wiley; M M Howton; M D Siperstein
Journal:  J Biol Chem       Date:  1977-01-25       Impact factor: 5.157

7.  Measurement of cholesterol synthesis in kinetically defined pools using fecal steroid analysis and double labeling technique in man.

Authors:  M Kekki; T A Miettinen; B Wahlström
Journal:  J Lipid Res       Date:  1977-01       Impact factor: 5.922

8.  Plasma mevalonate as a measure of cholesterol synthesis in man.

Authors:  T S Parker; D J McNamara; C D Brown; R Kolb; E H Ahrens; A W Alberts; J Tobert; J Chen; P J De Schepper
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

9.  Studies of the in vivo metabolism of mevalonic acid in the normal rat.

Authors:  K H Hellstrom; M D Siperstein; L A Bricker; L J Luby
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

10.  Measurement of cholesterol synthesis in man by isotope kinetics of squalene.

Authors:  G C Liu; E H Ahrens; P H Schreibman; P Samuel; D J McNamara; J R Crouse
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

View more
  1 in total

1.  Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.

Authors:  T Yoshida; A Honda; J Shoda; M Abei; Y Matsuzaki; N Tanaka; H Miyazaki; T Osuga
Journal:  Lipids       Date:  1997-08       Impact factor: 1.880

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.